The purpose of this quality improvement project is to outline three courses of action for molluscum contagiosum in the primary care setting, apply the concept of lean healthcare to address the treatment of molluscum contagiosum, and introduce in-office treatment of molluscum in a primary care pediatrics clinic. Prior to this project, the courses of action available to primary care pediatricians at Wright-Patterson Air Force Base (WPAFB) when identifying molluscum contagiosum are 1) Provide patient education on molluscum contagiosum including its self-limited nature, expected time course (typically within a year), and instructions to limit spread to self and others 2) Perform in-office cryotherapy with liquid nitrogen or prescribe topical tretinoin 3) Refer to dermatology for treatment with topical cantharidin On July 21, 2023, the FDA approved topical cantharidin in the form of an administration system called Y-canth for patients age two years and older. Y-canth is a single-use applicator containing 0.7% cantharidin. Administration involves breaking a glass vial in the applicator using a crushing device (required to be replaced every 12 uses), then applying a thin layer of cantharidin to the molluscum papules. The price of Y-canth has not been established, but has been estimated to cost approximately 0 per applicator. Prior to the development of Y-canth administration system, topical 0.7% cantharidin has been a long-standing treatment used by dermatologists for molluscum (an unapproved use). It is applied using the handle end of a cotton tip applicator, which allows for targeted application to the lesion without application to surrounding skin. This is simple process creates minimal waste and requires very little provider education and training. Furthermore, one 7.5ml bottle of topical cantharidin 0.7% costs 4.95, and the WPAFB dermatology clinic uses one bottle approximately every 4 months. The concept of lean healthcare was applied to implement in-office treatment of molluscum with topical cantharidin. This course of action allows for immediate treatment, eliminating the need for a referral to dermatology. This is particularly beneficial at this military treatment facility, as the dermatology clinic is staffed by one dermatologist and one physician’s assistant. In contrast, the pediatrics clinic has robust staffing by numerous attending and resident physicians. Additional cost is saved by training providers on the use of manual application of topical cantharidin. At 4.95 per bottle (estimated 100 patient encounters per bottle), the cost of treatment is about 500 times lower than the estimated cost of newly approved Y-canth at 0. This project applies the concept of lean health care by equipping primary care pediatricians with a low-cost, longstanding treatment option for the elective treatment of a benign dermatologic condition. An additional application is accomplished by examining a currently cost-prohibitive FDA-approved treatment method and recognizing the ability to apply the same topical medication via a traditional application method. Finally, implementation of this quality improvement project enables pediatricians at WPAFB to continue to reduce the cost and burden of treating molluscum contagiosum and continue to expand their scope of dermatologic care provided in the primary care setting.